Tyrosine kinase inhibitors and immunosuppressants perturb the myo- inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells

Mohamed Atta, Stephen C. Dahl, H. Moo Kwon, Joseph S. Handler

Research output: Contribution to journalArticle

Abstract

Background. The sodium/myo-inositol cotransporter (SMIT) and the betaine cotransporter (BGT1) are essential for the accumulation of myo-inositol and betaine, and hence cell survival in a hypertonic environment. The underlying molecular mechanism involves an increase in transcription of the SMIT and BGT1 genes through binding of a trans-acting factor to enhancer elements in the 5' flanking region of both genes, resulting in increased mRNA abundance and increased activity of the cotransporters. Current evidence regarding transcriptional and post-transcriptional regulation indicates that both cotransporters are regulated in parallel. Methods. To investigate the signal transduction of hypertonic stress, we examined the effect of tyrosine kinase inhibitors and immunosuppressants on the hypertonicity-induced activity of the two cotransporters in Madin-Darby canine kidney (MDCK) cells. Results. None of the agents studied affected BGT1 activity in isotonic or hypertonic conditions. Treatment of MDCK cells with genistein, a tyrosine kinase inhibitor, increased SMIT activity in hypertonic but not isotonic conditions. The stimulation of SMIT by genistein was accompanied by a parallel increase in mRNA abundance. In contrast, treating cells with tyrphostin A23, another tyrosine kinase inhibitor, or cyclosporine A, an immunosuppressant, inhibited SMIT activity in hypertonic cells. FK506, another immunosuppressant, increased SMIT activity, but only in isotonic conditions. Conclusions. These results provide the first evidence of divergent regulatory pathways modulating SMIT and BGT activity.

Original languageEnglish (US)
Pages (from-to)956-962
Number of pages7
JournalKidney International
Volume55
Issue number3
DOIs
StatePublished - 1999

Fingerprint

Betaine
Madin Darby Canine Kidney Cells
Inositol
Immunosuppressive Agents
Protein-Tyrosine Kinases
Sodium
Genistein
Messenger RNA
Trans-Activators
5' Flanking Region
Osmotic Pressure
Tacrolimus
Cyclosporine
Genes
Signal Transduction
Cell Survival

Keywords

  • Cell volume
  • Cotransport
  • Hypertonicity
  • Osmolytes
  • Protein phosphorylation
  • Transcription

ASJC Scopus subject areas

  • Nephrology

Cite this

Tyrosine kinase inhibitors and immunosuppressants perturb the myo- inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells. / Atta, Mohamed; Dahl, Stephen C.; Kwon, H. Moo; Handler, Joseph S.

In: Kidney International, Vol. 55, No. 3, 1999, p. 956-962.

Research output: Contribution to journalArticle

@article{1445884b6d904a31a3b35f380359d1fa,
title = "Tyrosine kinase inhibitors and immunosuppressants perturb the myo- inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells",
abstract = "Background. The sodium/myo-inositol cotransporter (SMIT) and the betaine cotransporter (BGT1) are essential for the accumulation of myo-inositol and betaine, and hence cell survival in a hypertonic environment. The underlying molecular mechanism involves an increase in transcription of the SMIT and BGT1 genes through binding of a trans-acting factor to enhancer elements in the 5' flanking region of both genes, resulting in increased mRNA abundance and increased activity of the cotransporters. Current evidence regarding transcriptional and post-transcriptional regulation indicates that both cotransporters are regulated in parallel. Methods. To investigate the signal transduction of hypertonic stress, we examined the effect of tyrosine kinase inhibitors and immunosuppressants on the hypertonicity-induced activity of the two cotransporters in Madin-Darby canine kidney (MDCK) cells. Results. None of the agents studied affected BGT1 activity in isotonic or hypertonic conditions. Treatment of MDCK cells with genistein, a tyrosine kinase inhibitor, increased SMIT activity in hypertonic but not isotonic conditions. The stimulation of SMIT by genistein was accompanied by a parallel increase in mRNA abundance. In contrast, treating cells with tyrphostin A23, another tyrosine kinase inhibitor, or cyclosporine A, an immunosuppressant, inhibited SMIT activity in hypertonic cells. FK506, another immunosuppressant, increased SMIT activity, but only in isotonic conditions. Conclusions. These results provide the first evidence of divergent regulatory pathways modulating SMIT and BGT activity.",
keywords = "Cell volume, Cotransport, Hypertonicity, Osmolytes, Protein phosphorylation, Transcription",
author = "Mohamed Atta and Dahl, {Stephen C.} and Kwon, {H. Moo} and Handler, {Joseph S.}",
year = "1999",
doi = "10.1046/j.1523-1755.1999.055003956.x",
language = "English (US)",
volume = "55",
pages = "956--962",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Tyrosine kinase inhibitors and immunosuppressants perturb the myo- inositol but not the betaine cotransporter in isotonic and hypertonic MDCK cells

AU - Atta, Mohamed

AU - Dahl, Stephen C.

AU - Kwon, H. Moo

AU - Handler, Joseph S.

PY - 1999

Y1 - 1999

N2 - Background. The sodium/myo-inositol cotransporter (SMIT) and the betaine cotransporter (BGT1) are essential for the accumulation of myo-inositol and betaine, and hence cell survival in a hypertonic environment. The underlying molecular mechanism involves an increase in transcription of the SMIT and BGT1 genes through binding of a trans-acting factor to enhancer elements in the 5' flanking region of both genes, resulting in increased mRNA abundance and increased activity of the cotransporters. Current evidence regarding transcriptional and post-transcriptional regulation indicates that both cotransporters are regulated in parallel. Methods. To investigate the signal transduction of hypertonic stress, we examined the effect of tyrosine kinase inhibitors and immunosuppressants on the hypertonicity-induced activity of the two cotransporters in Madin-Darby canine kidney (MDCK) cells. Results. None of the agents studied affected BGT1 activity in isotonic or hypertonic conditions. Treatment of MDCK cells with genistein, a tyrosine kinase inhibitor, increased SMIT activity in hypertonic but not isotonic conditions. The stimulation of SMIT by genistein was accompanied by a parallel increase in mRNA abundance. In contrast, treating cells with tyrphostin A23, another tyrosine kinase inhibitor, or cyclosporine A, an immunosuppressant, inhibited SMIT activity in hypertonic cells. FK506, another immunosuppressant, increased SMIT activity, but only in isotonic conditions. Conclusions. These results provide the first evidence of divergent regulatory pathways modulating SMIT and BGT activity.

AB - Background. The sodium/myo-inositol cotransporter (SMIT) and the betaine cotransporter (BGT1) are essential for the accumulation of myo-inositol and betaine, and hence cell survival in a hypertonic environment. The underlying molecular mechanism involves an increase in transcription of the SMIT and BGT1 genes through binding of a trans-acting factor to enhancer elements in the 5' flanking region of both genes, resulting in increased mRNA abundance and increased activity of the cotransporters. Current evidence regarding transcriptional and post-transcriptional regulation indicates that both cotransporters are regulated in parallel. Methods. To investigate the signal transduction of hypertonic stress, we examined the effect of tyrosine kinase inhibitors and immunosuppressants on the hypertonicity-induced activity of the two cotransporters in Madin-Darby canine kidney (MDCK) cells. Results. None of the agents studied affected BGT1 activity in isotonic or hypertonic conditions. Treatment of MDCK cells with genistein, a tyrosine kinase inhibitor, increased SMIT activity in hypertonic but not isotonic conditions. The stimulation of SMIT by genistein was accompanied by a parallel increase in mRNA abundance. In contrast, treating cells with tyrphostin A23, another tyrosine kinase inhibitor, or cyclosporine A, an immunosuppressant, inhibited SMIT activity in hypertonic cells. FK506, another immunosuppressant, increased SMIT activity, but only in isotonic conditions. Conclusions. These results provide the first evidence of divergent regulatory pathways modulating SMIT and BGT activity.

KW - Cell volume

KW - Cotransport

KW - Hypertonicity

KW - Osmolytes

KW - Protein phosphorylation

KW - Transcription

UR - http://www.scopus.com/inward/record.url?scp=0033036786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033036786&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.1999.055003956.x

DO - 10.1046/j.1523-1755.1999.055003956.x

M3 - Article

C2 - 10027932

AN - SCOPUS:0033036786

VL - 55

SP - 956

EP - 962

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 3

ER -